ABCL-064: Prognostic Value of Red Distribution Width (RDW) at Diagnosis in Diffuse Large B-Cell Lymphoma

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 20; p. S262
• Main Authors: Abdelsalam, Eman M. Nagiub, Eltybe, Hanan, Abdallah, Ghada E.M., Saleh, Mostafa F. Mohammed
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2020
• Subjects: ABCL; aggressive B-cell lymphoma; diffuse large B-cell lymphoma; non-Hodgkin lymphoma; red distribution width (RDW); red distribution width (RDW); non-Hodgkin lymphoma; diffuse large B-cell lymphoma; ABCL; aggressive B-cell lymphoma
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(20)30867-3

Recent studies indicate that higher Red Distribution Width (RDW) at diagnosis in lymphoproliferative malignancies is associated with poor outcome related to a higher proinflammatory status and comorbidities. To assess the prognostic value of RDW at diagnosis in diffuse large B-cell lymphoma (DLBCL). A retrospective cohort study of patients diagnosed with DLBCL between January 2011 and January 2018 in South Egypt Cancer Institute were included in the analysis. The South Egypt Cancer Institute is a tertiary care referral centre located in Upper Egypt. Eighty-three patients with aggressive DLBCL were recruited to the study. The median age at diagnosis was 49 years. Thirty-nine patients were males with a percentage of 47% and 44 patient were females with a percentage of 53%. Data of CBC including RDW, BM microscopic evaluation, and biochemical markers as albumin, LDH at diagnosis were determined. Records for clinical data as B symptoms and performance status, treatment outcome, and survival rates were evaluated. Cutoff of RDW > 15 was considered as high-risk. High RDW > 15 was found in 37 patients (44.6%). For treatment outcome, patients with high RDW >15 demonstrated no difference from the patients with normal RDW as regard achieving complete remission (37% vs 51.4%; p=0.2). Regarding disease characteristics, no variations were found between the group with high RDW and the group with normal RDW in respect of the Ann Arbor stage, B symptoms, and BM infiltration at diagnosis. The median follow-up was 16 months (range 2-76 months) and 19 patients experienced death with a percentage of 22.9%. Cox-regression analysis showed that prognostic factors for overall survival (OS) were: male sex (HR=0.27, p=0.05), performance status (HR=0.2, p=0.01), and LDH (HR=1, p=0.04) and no role for age, stage at diagnosis, presence of bone marrow infiltration at diagnosis, or RDW. High RDW failed to show prognostic value in our cohort of DLBCL regard the overall survival or achieving CR post first-line therapy.